Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
A series of novel (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones were prepared and examined for utility as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass
Benjamin E
BE
Procter & Gamble Pharmaceuticals, Health Care Research Center, Mason, OH 45040, USA. bblass2@fuse.net
Coburn
Keith
K
Lee
Wenlin
W
Fairweather
Neil
N
Fluxe
Andrew
A
Wu
Shengde
S
Janusz
John M
JM
Murawsky
Michael
M
Fadayel
Gina M
GM
Fang
Bin
B
Hare
Michelle
M
Ridgeway
Jim
J
White
Ron
R
Jackson
Chris
C
Djandjighian
Laurent
L
Hedges
Richard
R
Wireko
Fred C
FC
Ritter
Amanda L
AL
D001281:Atrial Fibrillation / Q000378:metabolism*; D002460:Cell Line; D018360:Crystallography, X-Ray; D006801:Humans; D051666:Kv1.5 Potassium Channel / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008697:Methane / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D008958:Models, Molecular; D015394:Molecular Structure; D026902:Potassium Channel Blockers / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D051666:Kv1.5 Potassium Channel; D026902:Potassium Channel Blockers; D008697:Methane